ClinicalTrials.gg
WithdrawnNCT05104905RENACOLUpdated May 11, 2022

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

A Phase 1/2 interventional study of bexmarilimab in Carcinoma, Renal Cell and Carcinoma Colon, sponsored by Faron Pharmaceuticals Ltd. Withdrawn at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by Faron Pharmaceuticals Ltd · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly accumulating in another ongoing study, sponsor considered that RENACOL study is no longer needed to assess the safety profile of bexmarilimab

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Carcinoma, Renal Cell with a site in Finland — 2 open to participants now, 9 under way, 8 of them phase 3. Carcinoma, Renal Cell · Finland.

Enrollment
22nd of 22
0 · median 581
Started
2021
with 4 others
Phase 1/2
2 of 27
1 open now
Registered
22nd of 27
by date
Lead sponsor
1 of 27
Faron Pharmaceuticals Ltd

Among the 27 studies in Carcinoma, Renal Cell with a site in Finland, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2021, is one of 2 in phase 1/2, and was the 22nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

2 of the 27 studies in Carcinoma, Renal Cell with a site in Finland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma, Renal Cell with a site in Finland, or all of them as a file.
02

Study summary

Bexmarilimab treatment has demonstrated tolerable safety profile and anticancer efficacy in some subjects with advanced malignancies. This is the first study to investigate the effect of single neoadjuvant dose of anti-CLEVER-1 antibody bexmarilimab prior to radical surgery of renal cell and colon cancers. We expect that the single dose will demonstrate measurable effects on the tumour immunological microenvironment as well as systemic effects on subject´s immunological status and that this evidence may be used to guide future neoadjuvant studies. There will be a dose escalation to investigate the effect of different doses of bexmarilimab. In addition to subjects receiving single neoadjuvant dose of bexmarilimab, there will be an observational cohort without Investigational Medicinal Product (IMP) for either cancer. All patients participating in the study (whether in investigational or observational cohort) will attend each visit and are assessed for the same endpoints.

03

Conditions studied

  • Carcinoma, Renal Cell
  • Carcinoma Colon
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form.
  2. Ability and stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Male or female, aged > 18 years.
  4. Adequate general health ( 0 or 1) to undergo planned radical surgery for renal cell or colon cancer.
  5. Adequate bone marrow, liver and kidney function defined as: Blood white blood cell ≥ lower limit of normal Blood ≥ 1x109/L Blood count ≥ 100x109/L Blood ≥ 9.0 g/dL > 40 mL/min calculated by Cockcroft-Gault formula (AST) ≤ 3 X (ULN) Alanine Aminotransferase (ALT) ≤ 3 X ULN ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL
  6. confirmed clear cell renal cell cancer planned to be treated with surgery with curative intent (Renal cell cancer cohort). In renal cell observation cohort, histological confirmation not mandatory.

    or Histologically confirmed adenocarcinoma of the colon planned to be treated with surgery with curative intent (Colon cancer cohort).

    Additional inclusion criteria for subjects planned to have a single dose of CLEVER-1 antibody bexmarilimab:

  7. For females of : use of highly effective * for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of single neoadjuvant dose of bexmarilimab administration.
  8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 12 weeks after the administration of single neoadjuvant dose of bexmarilimab.

    • Women of i.e. not or surgically sterilised must use highly effective methods of contraception. For example, combined estrogen and progestogen hormonal contraception to inhibit ovulation; progestogen-only hormonal contraception to inhibit ovulation; intra-uterine device (IUD); intrauterine hormone-releasing system (IUS) or vasectomised partner to prevent pregnancy or abstain. Abstinence must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence such as calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception during heterosexual activity for the duration of the trial and for at least 12 weeks following the study drug administration. In addition, barrier contraception (with or without spermicide) may be used but this should not be considered as an adequate form of contraception on its own.

Fertile men whose partners could be of childbearing potential should routinely use a condom for 12 weeks after the study drug administration. The partner, if not pregnant, should also use a reliable form of contraception such as the oral contraceptive pill or an IUD.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of disease making subject not eligible for surgical resection, except for local nodal metastatic disease.
  2. History of previous treatment for renal cell cancer (renal cell cancer cohorts) or colon cancer (colon cancer cohorts).
  3. Less than 3 months since the last dose of any cancer therapy prior to consenting.
  4. Less than 4 weeks since any major surgery.
  5. Treatment with any agent within 4 weeks before consenting.
  6. History of another without curative treatment or suspicion of disease recurrence.
  7. Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure (NYHA) class 2, Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial.
  8. Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment.
  9. Confirmed infection.
  10. Confirmed or C virus infection.
  11. Symptomatic cytomegalovirus infection.
  12. Subjects with active disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia).
  13. The subject requires systemic or other treatment.
  14. Subjects with organ transplants.
  15. Subjects in dialysis.
  16. Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit.
  17. Subject is unwilling or unable to comply with treatment and trial instructions.
  18. Pregnancy or lactation.
  19. Medical history of chronic ulcers, abnormal liver function or previous liver problems/diseases
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Renal cell intervention 1.0 mg/kg

    Drug: bexmarilimab

  • Experimental
    Renal cell intervention 3.0 mg/kg

    Drug: bexmarilimab

  • Experimental
    Renal cell intervention 10 mg/kg

    Drug: bexmarilimab

  • No intervention
    Renal cell Observation
  • Experimental
    Colon cancer intervention 1.0 mg/kg

    Drug: bexmarilimab

  • Experimental
    Colon cancer intervention 3.0 mg/kg

    Drug: bexmarilimab

  • Experimental
    Colon cancer intervention 10 mg/kg

    Drug: bexmarilimab

  • No intervention
    Colon cancer Observation

Interventions

  • A single neoadjuvant dose will be administered prior to surgery.

06

What researchers measure

Primary outcomes

  1. Adverse Events ≥Grade 3 during the 28 days (4 weeks) following the single dose of bexmarilimab and surgical adverse events ≥Grade 3 during the 14days (2 weeks) following the surgery

    Adverse Events ≥Grade 3 according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 during the 28 days (4 weeks) following the single dose of bexmarilimab and surgical adverse events ≥Grade 3 according to the Clavien-Dindo classification occurring during the 14 days (2 weeks) following the surgery

    Time frame: 28 days and 14 days

Secondary outcomes

  1. Adverse events until the follow-up visit on Day 84

    Time frame: Day 84

  2. Radiological response rate according to the response evaluation criteria in solid tumours (RECIST 1.1) (Day 13)

    Time frame: Day 13

  3. Pathological response rate evaluated with Ryan tumour regression grade (Day 14), percentage of tumour cell necrosis

    Time frame: Day 14

  4. Long-term clinical benefit measured by disease-free survival assessed at 1, 3 and 5 years

    Time frame: 1, 3, and 5 years

07

Study locations

1 site
  • Turku University Hospital
    Turku, 20521, Finland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Nov 3, 2021
StartActual
Oct 7, 2021
Primary completionActual
Jan 28, 2022
CompletionActual
Jan 28, 2022
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05104905
Lead sponsor
Faron Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Oct 7, 2021
Primary completion
Jan 28, 2022
Completion
Jan 28, 2022
Last update
May 11, 2022

Study contacts

Peter Boström
principal investigator · Turku University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bexmarilimab

Start the discussion